TMO logo
Thermo Fisher Scientific Inc.
TMO
583.45 (0.00%) 0.00
Health Care
Life Sciences Tools and Services
Thermo Fisher Scientific Inc. provides life sciences solutions analytical instruments specialty diagnostics and laboratory products and biopharma services in the North America Europe Asia-Pacific and internationally. The company’s Life Sciences Solutions segment offers reagents instruments and consumables for biological and medical research discovery and production of drugs and vaccines as well as diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments consumables software and services for pharmaceutical biotechnology academic government environmental and other research and industrial markets as well as clinical laboratories. The company’s Specialty Diagnostics segment includes clinical diagnostics offering liquid ready-to-use and lyophilized immunodiagnostic reagent kits as well as calibrators controls protein detection assays and instruments; immunodiagnostics offers develops manufactures and markets complete blood test systems to support the clinical diagnosis and monitoring of allergy asthma and autoimmune diseases; microbiology offers dehydrated and prepared culture media collection and transport systems instrumentation and consumables; transplant diagnostics products include human leukocyte antigen typing and testing for organ transplant market; and healthcare market channel offers consumables diagnostic kits and reagents equipment instruments solutions and services. Its Laboratory Products and Biopharma Services segment provides laboratory products research and safety market channel and pharma services and clinical research. It offers products and services through a direct sales force customer-service professionals electronic commerce and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham Massachusetts.

Quality Checklist 5/8

5Y Shares Out Change < 0%
Debt/Equity < 1
Current Ratio > 1
Net Margin > 10%
Est. EPS Growth > 5%
ROIC > 10%
Quick Ratio > 1
Past Net Income CAGR > 0%
0.0%of Portfolio

My holdings

Day change:
Total change:
Shares:
Cost basis:
Market cap: $219.21(B)
EV: $251.48(B)
Total Equity: $51.15(B)
Earnings date: Jan-29-2026
P/E: 33.65
Forward P/E: 25.67
P/FCF: 35.86
P/S: 5.06
P/B: 4.30
EPS: $17.3
EPS (fwd): $22.7
FCF/share: $16.3
Revenue/share: $115.4
Book value/share: $135.8
ROIC: 7.7%
ROA: 6.5%
ROE: 13.1%
Debt/Equity: 0.70
Current Ratio: 1.50
Gross margin: 41.4%
Operating margin: 18.4%
Net margin: 15.0%
Dividend/share: $1.7
Div. yield: 0.29%

TMO Valuation & Price Targets

Current Price
$583

Favorite Valuation Methods

More Valuation Methods

DCF (simple)
N/A
N/A
DCF (exit mult.)
N/A
N/A
DDM
N/A
N/A
EPS growth
N/A
N/A
Revenue growth
N/A
N/A
Peter Lynch FV
N/A
N/A
Graham No.
N/A
N/A

PEvaluation

34% overvalued
Low
$290
Mid
$386
High
$483
Current price
$583
Fair P/E
Margin of safety
EPS
Market Model
ROICRevenue growthFCF MarginShares outstan...Debt/EquityDebt/EBITDA
Economic moat: Medium

EPS Estimates

LowAvgHigh#
FY+122.522.722.826
FY+224.024.625.927
FY+326.327.328.419
FY+429.330.532.36
FY+532.434.336.93

Analyst Price Targets

8% undervalued
Low
$533
Mid
$630
High
$750
Current price
$583

Analyst Recommendations

Strong Buy4
Buy17
Hold5
Sell0
Strong Sell0

2-stage DCF

First Stage Duration: 5 Years
Starting Free Cash Flow
First Stage Growth Rate
LowMidHigh
Terminal Growth Rate
LowMidHigh
Discount Rate

Discounted Cash Flow

Forecast years: 5 Years
Terminal Growth Rate
LowMidHigh
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Discounted Cash Flow (exit mult.)

Forecast years: 5 Years
Exit FCF Multiple
LowMidHigh
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Dividend Discount Model

Annual Dividend
First Stage Length (Years): 0 Years
First Stage Growth Rate
Final Growth Rate
Discount Rate

EPS Growth

Forecast years: 5 Years
Starting EPS
EPS Growth Rate
LowMidHigh
Final P/E
LowMidHigh
Discount Rate

Revenue Growth Valuation

Forecast Years: 10 Years
Base Revenue
Revenue Growth Rate
LowMidHigh
Final Net Margin
LowMidHigh
Final P/E Ratio
LowMidHigh
Discount Rate

Peter Lynch Fair Value

Earnings Per Share
Growth Rate

Graham Formula

Earnings Per Share
EPS Growth (7-10 years)
Government Bond Rate